Dr Balena is currently affiliated with Eli Lilly and Company Ltd, Erl Wood Manor, Windlesham Surrey, UK.
Short Report: Treatment
Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial
Article first published online: 13 DEC 2012
© 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK
Volume 30, Issue 1, pages 109–113, January 2013
How to Cite
Nauck, M., Horton, E., Andjelkovic, M., Ampudia-Blasco, F. J., Parusel, C. T., Boldrin, M., Balena, R. and for the T-emerge 5 Study Group (2013), Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial. Diabetic Medicine, 30: 109–113. doi: 10.1111/dme.12003
(Clinical Trials Registry No; NCT 00755287)
- Issue published online: 13 DEC 2012
- Article first published online: 13 DEC 2012
- Accepted manuscript online: 31 AUG 2012 10:45PM EST
- Accepted 28 August 2012
Figure S1. Patient disposition.
Table S1. Titration algorithm for insulin glargine.
Table S2. Change from baseline in lipidparameters and blood pressure over 24 weeks (intent-to-treatpopulation).
Table S3. Baseline characteristics (intent-to-treat population).
Appendix S1. List of study investigators.
|dme12003_sm_AppendixS1-TableS1-S3-FigS1.doc||151K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.